Liminatus Pharma (LIMN) Income towards Parent Company (2024 - 2026)

Liminatus Pharma has reported Income towards Parent Company for 3 years, with the latest figure at -$1.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 241.82% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.7 million (down 63.17% YoY) and the FY2025 annual result came in at -$5.2 million, down 47.67% from the prior year.
• Income towards Parent Company fell to -$1.1 million in Q1 2026 per LIMN's latest filing, from -$713610.0 in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$327526.0 in Q1 2025 and troughed at -$1.2 million in Q2 2025.
• A 3-year average of -$747850.6 and a median of -$716916.0 in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2025 and 2026: Income towards Parent Company decreased 19.76% in 2025, then plunged 241.82% in 2026.
• Over 3 years, Income towards Parent Company stood at -$383216.0 in 2024, then slumped by 86.22% to -$713610.0 in 2025, then sank by 56.88% to -$1.1 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$1.1 million, -$713610.0, and -$720222.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.